Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Real-Time Location System provider for healthcare, is pleased to ... Real-Time Location System . The new messaging better captures ... – , Industry-Leading Accuracy , ... Applications Easy Installation and Maintenance ...
... been mysteriously falling for at least five years in the ... (CCD) is still largely unknown. In a report ... , researchers report that a widely used in-hive medication may ... and that this interaction may be at least partially responsible ...
... and SHENZHEN, China, Nov. 2, 2011 Advanced BioMedical ... internal fixation devices, is pleased to announce the formation ... comprised of three distinguished physicians and scientists. The combined ... critical scientific and strategic input as the Company continues ...
Cached Biology Technology:CenTrak, a Leading Real-Time Location System Provider, Unveils New Branding 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 3Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 4Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 5Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 6Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 7
(Date:4/24/2014)... recently introduced Clinical OMICs ... of OMICs technologies in clinical settings. These advanced ... transform medical care just as they revolutionized basic ... "GEN,s editors and reporters have written about the ... etc. for years," said John Sterling, editor-in-chief of ...
(Date:4/24/2014)... cheap way of making a high-powered lens that can ... Costing less than a cent, the lenses promise a ... remote areas. , The lens fabrication technique was invented ... (ANU) Research School of Engineering, who collaborated with Dr ... to find ways to transform the lentil-sized lens into ...
(Date:4/24/2014)... University of North Carolina at Chapel Hill have developed ... plaque that is at high risk of breaking off ... is the plaque that builds up in arteries as ... meaning that they are more likely to detach from ... , "Existing state-of-the-art technologies are capable of determining if ...
Breaking Biology News(10 mins):Droplet lens 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... 2009 Landfilled waste decomposes in the absence ... methane. Landfills are classified as the second-largest human-made ... gas contains numerous non-methane hydrocarbons that are either ... biochemical reactions during waste degradation. Microbial methane ...
... tissues need continuous irrigation and drainage. Blood vessels feeding ... via the lymphatic system. While much is known about ... true for lymph vessels. Now though, Norrmn et al. ... drainage construction in the mouse embryo. The ...
... the composition and structure of a needlelike protein complex ... develop new strategies to thwart infection. The research, conducted ... National Laboratory, will be published April 26, 2009, in ... Molecular Biology . The scientists were studying a ...
Cached Biology News:Landfill cover soil methane oxidation underestimated 2Details of bacterial 'injection' system revealed 2
... antibiotic-based selection system for recombinant identification. Recombinant ... the need for costly color screening. This ... 100% accuracy in recombinant selection. pLivSelect is ... picking. This cloning kit can be used ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
...
Biology Products: